HER2/neu role in breast cancer: from a prognostic foe to a predictive friendG. Ferretti, Francesco Cognetti, Alessandra Felici et al.|Current Opinion in Obstetrics & Gynecology|2007Cited by 104
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Francesco Cognetti, Giulio Metro et al.|The Breast|2008Cited by 52
Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow?Alessandra Fabi, F. Cognetti, Antonello Vidiri et al.|Cancer Investigation|2006Cited by 42
Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?G. Ferretti, F. Cognetti, Emilio Bria et al.|CHEST Journal|2006Cited by 41
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG. Ferretti, Paolo Carlini, Emilio Bria et al.|British Journal of Cancer|2006Cited by 38